No data to show
XNAS
GRAL
Market cap1.53bUSD
Jun 20, Last price
45.63USD
1D
2.93%
1Q
50.89%
IPO
150.12%
Name
Grail Inc
Chart & Performance
P/E
—
P/S
13.07
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-23.68%
Rev. gr., 5y
%
Revenues
126m
+34.90%
Net income
-2.03b
L+38.30%
CFO
-577m
L-3.13%
Profile
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | 125,595 34.90% | 93,105 67.61% | 55,550 280.17% | |||||
Cost of revenue | 893,817 | 890,021 | 798,009 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (768,222) | (796,916) | (742,459) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (135,356) | (41,951) | (42,290) | |||||
Tax Rate | ||||||||
NOPAT | (632,866) | (754,965) | (700,169) | |||||
Net income | (2,027,005) 38.30% | (1,465,685) -72.85% | (5,399,098) 332.70% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (234) | (4,183) | ||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 13,260 | 14,809 | 13,335 | |||||
Long-term debt | 123,022 | 154,005 | 165,350 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 2,236 | 1,498 | 3,134 | |||||
Net debt | (627,188) | 67,302 | (67,443) | |||||
| Cash flow | ||||||||
Cash from operating activities | (577,156) | (595,800) | (561,313) | |||||
CAPEX | (5,208) | (12,887) | (22,859) | |||||
Cash from investing activities | (551,011) | (12,887) | (22,859) | |||||
Cash from financing activities | 1,244,300 | 463,766 | 604,817 | |||||
FCF | (598,919) | (725,623) | (898,892) | |||||
| Balance | ||||||||
Cash | 763,470 | 97,287 | 241,596 | |||||
Long term investments | 4,225 | 4,532 | ||||||
Excess cash | 757,190 | 96,857 | 243,350 | |||||
Stockholders' equity | (9,801,845) | 3,646,187 | 4,646,161 | |||||
Invested Capital | 12,375,627 | 4,278,348 | 4,501,954 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 31,901 | 31,053 | 31,053 | |||||
Price | 17.85 | |||||||
Market cap | 569,437 | |||||||
EV | (57,751) | |||||||
EBITDA | (610,166) | (638,219) | (587,696) | |||||
EV/EBITDA | 0.09 | |||||||
Interest | ||||||||
Interest/NOPBT | ||||||||